Related Experiment Videos
FDA's requirements for in-vitro performance data for prosthetic heart valves
D M Johnson1, D J Chwirut, W F Regnault
1Center for Devices & Radiological Health Food & Drug Administration Rockville, Maryland.
The Journal of Heart Valve Disease
|May 1, 1994
Summary
The Food and Drug Administration (FDA) updated its Replacement Heart Valve Guidance, detailing necessary in vitro data for prosthetic heart valve approval. This summary explains FDA's in vitro data requirements and their interpretation in the device approval process.
Area of Science:
- Biomedical Engineering
- Medical Device Regulation
- Cardiovascular Devices
Background:
- The Food and Drug Administration's Center for Devices and Radiological Health has revised its "Replacement Heart Valve Guidance."
- This guidance outlines essential data for the Premarket Approval Applications of new prosthetic heart valves.
- It specifies requirements for in vitro, animal, and clinical data.
Framework:
- Focuses on the in vitro data requirements stipulated by the FDA guidance.
- Explains the significance of specific in vitro data points.
- Details how the FDA interprets this data during the device approval process.
Implementation:
- Summarizes the FDA's expectations for in vitro testing protocols.
- Provides clarity on the types of results and analyses required.
- Aids manufacturers in preparing comprehensive Premarket Approval Applications.
Implications:
- Facilitates a smoother and more efficient FDA approval process for novel heart valve technologies.
- Ensures robust data submission for enhanced patient safety and device efficacy.
- Contributes to the standardization of regulatory requirements for cardiovascular devices.